List of Excipients in Branded Drug QUDEXY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Upsher-Smith Laboratories LLC	QUDEXY	topiramate	0245-1071	CELLULOSE, MICROCRYSTALLINE
Upsher-Smith Laboratories LLC	QUDEXY	topiramate	0245-1071	DIETHYL PHTHALATE
Upsher-Smith Laboratories LLC	QUDEXY	topiramate	0245-1071	ETHYLCELLULOSE

Qudexy XR Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: August 24, 2026

Qudexy XR is an extended-release topiramate capsule developed by Upsher-Smith Laboratories and approved by the U.S. Food and Drug Administration in 2013. Its commercial value is tied to modified-release multiparticulate technology, once-daily dosing, sprinkle administration, and differentiation from immediate-release topiramate products. The strongest commercial opportunities are generic or alternative extended-release capsules, pediatric-friendly sprinkle products, excipient substitutions, and manufacturing platforms that reproduce the release profile without copying protected formulation claims.

What is Qudexy XR and how does its formulation work?

Qudexy XR contains topiramate, an antiepileptic drug, in an extended-release capsule dosage form. The product is indicated for epilepsy-related seizure disorders and migraine prevention in adults and adolescents, subject to the approved labeling and age-specific limitations.[1]

Unlike conventional immediate-release topiramate tablets, Qudexy XR uses drug-loaded multiparticulates. The capsule can be swallowed whole or opened and sprinkled over a small amount of soft food, provided the contents are not chewed or crushed.[1]

Qudexy XR product profile

Attribute	Qudexy XR
Active ingredient	Topiramate
Dosage form	Extended-release capsule
Manufacturer	Upsher-Smith Laboratories
FDA approval	2013
NDA	202895
Strengths	25 mg, 50 mg, 100 mg, 150 mg, 200 mg
Administration	Once daily
Administration flexibility	Whole capsule or sprinkle over soft food
Therapeutic areas	Epilepsy and migraine prevention
Regulatory category	Small-molecule drug
Biosimilar relevance	None

Qudexy XR competes primarily with Trokendi XR, another extended-release topiramate capsule, and with generic immediate-release topiramate products. Trokendi XR uses a different proprietary extended-release technology and is marketed by Supernus Pharmaceuticals.

What excipients are used in Qudexy XR?

The Qudexy XR label identifies excipients associated with the multiparticulate extended-release system and capsule shell. Public labeling identifies sugar spheres, hypromellose, ethylcellulose, talc, gelatin, titanium dioxide, and colorants among the inactive ingredients.[1]

Functional role of the principal excipients

Excipient or material	Likely formulation function	Commercial relevance
Sugar spheres	Inert starter cores for drug-layered pellets	Supports multiparticulate manufacturing
Hypromellose	Film-forming polymer and release-control component	Controls hydration and diffusion
Ethylcellulose	Water-insoluble release-control polymer	Slows topiramate dissolution
Talc	Anti-tacking and processing aid	Supports coating uniformity
Gelatin	Hard-capsule shell	Enables sprinkle and whole-capsule administration
Titanium dioxide	Opacifier and colorant	Supports product identification
FD&C colorants	Strength differentiation	Reduces dispensing errors

The commercial importance of the excipient system lies in its interaction with coating thickness, pellet size distribution, drug loading, polymer permeability, capsule fill weight, and dissolution testing. A formulation that uses the same listed excipients can still produce a materially different product if the coating process, particle population, or polymer ratio changes.

How does the Qudexy XR release system create commercial value?

Multiparticulate delivery provides several formulation advantages:

1. It distributes topiramate across many coated particles rather than relying on one monolithic tablet matrix.
2. It can reduce the risk that damage to one unit causes immediate release of the full dose.
3. It permits sprinkle administration.
4. It creates multiple formulation parameters that can be protected by patent claims or used to establish bioequivalence.
5. It can reduce peak-to-trough fluctuations compared with immediate-release dosing.

The principal technical challenge is maintaining a reproducible extended-release profile across the full strength range. A manufacturer must control:

• Topiramate particle size and loading;
• Drug-layer uniformity on the sugar spheres;
• Hypromellose and ethylcellulose coating levels;
• Pellet friability;
• Coating defects;
• Capsule fill-weight variation;
• Dissolution in multiple media and pH conditions;
• Stability under heat and humidity;
• Sprinkle performance after contact with food.

The excipient strategy is therefore process-dependent. Merely matching the qualitative inactive-ingredient list is unlikely to establish pharmaceutical equivalence.

What formulation patents protect Qudexy XR?

Qudexy XR is protected primarily through formulation and modified-release patent rights rather than through a new chemical entity patent for topiramate. The relevant patent scope is expected to center on extended-release multiparticulates, polymer coatings, pellet architecture, release kinetics, and administration as a sprinkle formulation.

The precise active Orange Book listing, expiration dates, pediatric extensions, terminal disclaimers, and litigation status must be assessed against the current FDA Orange Book and USPTO records. Patent status can change through correction certificates, patent-term adjustments, reexamination, terminal disclaimers, or court decisions.

Patent claim categories relevant to Qudexy XR

Claim category	Typical protected subject matter	Design-around potential
Composition	Topiramate-containing extended-release particles	Substitute polymer systems or pellet architecture
Coating	Ethylcellulose, hypromellose, pore-forming agents, coating ratios	Change polymer blend or layer sequence
Particle structure	Drug-loaded cores, seal coats, functional membranes	Use matrix granules or alternative cores
Dissolution profile	Release windows at specified time points	Target a non-infringing profile while meeting bioequivalence
Dosage form	Capsules containing multiple extended-release units	Use tablets, minitablets, or different multiparticulates
Method of use	Once-daily treatment or sprinkle administration	Avoid method claims or use different dosing instructions
Manufacturing	Layering, coating, drying, and classification processes	Modify equipment and process conditions

For a generic applicant, the principal regulatory route is an abbreviated new drug application with a Paragraph IV certification if listed patents remain relevant. The applicant must establish pharmaceutical equivalence and bioequivalence while addressing any Orange Book patent claims.

When does Qudexy XR lose exclusivity?

Qudexy XR's FDA exclusivity and patent exclusivity are separate issues. FDA marketing exclusivity depends on the approval pathway and regulatory designation. Patent barriers depend on listed patents, expiration dates, patent-term adjustments, pediatric exclusivity, and litigation outcomes.

Exclusivity issue	Effect on competition
New-drug exclusivity	Can delay certain ANDA approvals
Listed formulation patents	Can block approval or create Paragraph IV litigation
Pediatric exclusivity	Can extend relevant patent or exclusivity protection by six months
Regulatory exclusivity expiration	Allows approval review but does not remove unexpired patents
Patent expiration	Removes the relevant patent barrier, subject to other listed rights
Settlement agreement	May establish an agreed generic entry date

Qudexy XR is a small molecule, so biosimilar exclusivity does not apply. Competition will arise through ANDAs, 505(b)(2) applications, branded alternatives, or reformulated topiramate products.

What Paragraph IV challenges and litigation affect Qudexy XR?

A Paragraph IV challenge would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Filing a proper Paragraph IV certification can trigger patent litigation and a potential 30-month stay of ANDA approval under the Hatch-Waxman framework.[2]

The relevant commercial questions are:

• Which Qudexy XR patents are listed in the current Orange Book?
• Which claims cover the capsule, pellet, coating, or release profile?
• Has an ANDA applicant sent a Paragraph IV notice?
• Did the NDA holder sue within the statutory period?
• Has a court entered a preliminary injunction or final judgment?
• Does a settlement permit an authorized or independent generic launch?
• Does the settlement restrict multiple generic entrants?

No biosimilar litigation pathway is relevant because topiramate is a chemically synthesized small molecule.

Which companies challenge or compete with Qudexy XR?

The principal branded competitor is Trokendi XR. Generic immediate-release topiramate manufacturers compete on price but do not fully duplicate Qudexy XR's once-daily extended-release profile.

Competitive comparison

Product	Company	Release type	Administration	Competitive position
Qudexy XR	Upsher-Smith	Extended release multiparticulates	Once daily; sprinkle option	Differentiated by flexible administration
Trokendi XR	Supernus	Extended release capsule	Once daily	Direct branded extended-release competitor
Topiramate IR generics	Multiple manufacturers	Immediate release	Usually divided dosing	Low-cost substitute
Potential generic Qudexy XR	ANDA applicants	Extended release	Expected to match reference product	Main post-exclusivity threat

Qudexy XR and Trokendi XR may be therapeutically similar but are not automatically substitutable solely because both contain extended-release topiramate. Product-specific bioequivalence, labeling, formulation, and state substitution rules determine the practical competitive relationship.

What excipient opportunities exist for Qudexy XR generics?

The largest opportunity is a non-infringing formulation that matches Qudexy XR's pharmacokinetic and dissolution profile without duplicating the originator's claimed polymer architecture.

1. Polymer substitution

A developer could evaluate alternative combinations of:

• Polyvinyl acetate-based release-control systems;
• Ammonio methacrylate copolymers;
• Ethylcellulose with different plasticizers;
• Hypromellose grades with different viscosity;
• Lipid or wax matrices;
• Hydrophilic matrix polymers in minitablets.

The formulation must maintain release consistency and avoid dose dumping under altered gastrointestinal conditions.

2. Layered multiparticulate systems

An alternative pellet may use:

• Different starter-core materials;
• Directly compressed drug-containing granules;
• Minitablets filled into capsules;
• Drug-loaded polymeric particles;
• Multiple pellet populations with distinct release rates.

This approach may create freedom-to-operate distance from claims directed to a specific drug-layered sugar-sphere structure.

3. Sprinkle and pediatric delivery

The sprinkle feature creates an opportunity for products aimed at patients who have difficulty swallowing capsules. Differentiation could include:

• Smaller pellet size;
• Improved mouthfeel;
• Reduced grittiness;
• Neutral or masked taste;
• Food-compatible administration;
• Packaging optimized for adherence;
• Dose flexibility through capsule strengths.

Any change must preserve the approved administration conditions and demonstrate that the sprinkled contents remain intact.

4. Excipient sourcing and supply resilience

Ethylcellulose, hypromellose, gelatin, talc, titanium dioxide, and capsule colorants are generally available from multiple suppliers. The commercial risk is not only supplier availability. A change in polymer grade can alter viscosity, coating permeability, dissolution, and stability.

A robust generic strategy should qualify more than one supplier where possible and establish comparability protocols for:

• Viscosity;
• Particle size;
• Moisture;
• Substitution type;
• Ash content;
• Microbial limits;
• Coating performance;
• Dissolution behavior.

What manufacturing and intellectual-property barriers exist?

Qudexy XR's manufacturing barrier is moderate to high for a conventional generic because the product requires multiparticulate coating and tight control of release performance. The equipment may include fluid-bed coaters, bottom-spray systems, precision layering equipment, capsule fillers, and specialized in-process testing.

Key barriers include:

• Uniform drug layering at commercial scale;
• Avoidance of pellet agglomeration;
• Consistent membrane coating;
• Control of pellet attrition during capsule filling;
• Stability of polymer films;
• Reproducible dissolution across strengths;
• Preservation of sprinkle integrity;
• Demonstration of bioequivalence for a modified-release product.

The strongest patent risk usually comes from claims that combine formulation composition with functional release limitations. A developer may avoid a narrow structural claim but still face risk under a claim directed to a dissolution profile or a method of treatment.

What regulatory status does Qudexy XR have?

Qudexy XR is FDA-approved under NDA 202895. The FDA-approved label identifies topiramate as the active ingredient and describes extended-release capsules in five strengths.[1]

The relevant regulatory pathways for competitors are:

• ANDA for a therapeutically equivalent generic;
• 505(b)(2) NDA for a materially different extended-release formulation;
• Supplemental NDA for changes to an approved product;
• Citizen petition or patent certification proceedings affecting approval timing.

The most commercially attractive route is an ANDA if the applicant can meet the reference product's bioequivalence requirements. A 505(b)(2) product may obtain greater formulation freedom but carries higher clinical, regulatory, and market-entry costs.

How strong is the Qudexy XR patent estate?

The estate is strongest where formulation claims are linked to measurable technical performance, including extended-release behavior, multiparticulate construction, and sprinkle administration. It is weaker where protection depends on broad use of conventional excipients without a narrow structural limitation.

Patent-strength indicators

Indicator	Assessment
Active ingredient protection	Limited because topiramate is an established molecule
Formulation protection	Material and commercially relevant
Manufacturing protection	Potentially significant if process claims are enforceable
Method-of-use protection	Secondary to formulation rights
Regulatory exclusivity	Time-limited and separate from patent rights
Design-around potential	Moderate, particularly through alternative pellet systems
Generic development difficulty	Higher than for an immediate-release tablet
Biosimilar barrier	Not applicable

The practical strength of the estate depends on the exact claims, prosecution history, written-description support, prior art, and Orange Book listing status. A freedom-to-operate review should analyze both literal infringement and equivalents for each formulation and process claim.

What commercial opportunities exist beyond a standard generic?

Commercial opportunities include:

• A lower-cost therapeutically equivalent extended-release capsule;
• A sprinkle product with improved taste and mouthfeel;
• A pediatric-focused presentation;
• A 505(b)(2) product with flexible dosing or alternative capsule technology;
• Contract manufacturing of topiramate multiparticulates;
• Licensing of polymer-coating or pellet-layering platforms;
• Regional commercialization in markets where Qudexy XR is unavailable;
• Authorized-generic supply arrangements;
• Combination packaging supporting adherence and dose titration.

Revenue exposure is concentrated in the extended-release topiramate segment rather than the entire topiramate market. Immediate-release generics constrain pricing, while the once-daily and sprinkle attributes support a premium if payers and prescribers recognize a clinical or adherence benefit.

Key Takeaways

• Qudexy XR is an extended-release topiramate capsule based on multiparticulate technology.
• Its excipient system includes sugar spheres, hypromellose, ethylcellulose, talc, gelatin, titanium dioxide, and colorants.
• The main formulation value lies in release control, once-daily dosing, and sprinkle administration.
• The main direct branded competitor is Trokendi XR.
• Generic development requires more than matching inactive ingredients. Pellet architecture, coating process, dissolution, and bioequivalence are decisive.
• Paragraph IV risk depends on the current Orange Book listing and enforceable formulation claims.
• Biosimilar competition is irrelevant because topiramate is a small molecule.
• The strongest commercial opportunities are alternative multiparticulates, pediatric sprinkle products, polymer substitutions, and 505(b)(2) formulations.
• Manufacturing scale-up and freedom to operate are the principal barriers to entry.

FAQs About Qudexy XR Excipient and Commercial Strategy

Is Qudexy XR the same as generic topiramate?

No. Qudexy XR contains topiramate but uses an extended-release capsule formulation. Immediate-release topiramate generics are not automatically equivalent to Qudexy XR.

Can Qudexy XR capsules be opened and sprinkled on food?

Yes, according to the FDA label, the capsule contents may be sprinkled on a small amount of soft food and swallowed without chewing.[1]

Does Qudexy XR have biosimilar competition?

No. Biosimilars apply to biologic products. Qudexy XR contains the chemically synthesized small molecule topiramate.

Which excipient is most important for Qudexy XR release control?

Ethylcellulose is a principal water-insoluble release-control polymer, while hypromellose contributes film formation and permeability control. Performance depends on the complete coating system and manufacturing process.

What is the most defensible generic design-around strategy?

A multiparticulate system using an alternative pellet structure or polymer architecture, supported by comparative dissolution, pharmacokinetic bioequivalence, and a claim-by-claim freedom-to-operate analysis, offers the clearest path.

References

1. U.S. Food and Drug Administration. (2023). Qudexy XR (topiramate) extended-release capsules: Prescribing information. Upsher-Smith Laboratories, LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). ANDA approvals and patent certification requirements under the Hatch-Waxman Amendments. Center for Drug Evaluation and Research.